Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26848733 | 0.85 | PIK3CA (0.45) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL25407787 | 0.82 | PIK3CA (0.49) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL30567664 | 0.82 | PIK3CA (0.49) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL26847330 | 0.80 | PIK3CD (0.41) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL18003803 | 0.79 | TRPV3 (0.43) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL18003295 | 0.79 | HTR2B (0.44) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL30567657 | 0.78 | RAB9A (0.44) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL25407809 | 0.78 | RAB9A (0.44) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL18003145 | 0.76 | KDM4E (0.46) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL26051112 | 0.75 | PIK3CA (0.43) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | PIK3CA 2018/4885PI4KB 2941/4885PIK3CD 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.